Type 2 Diabetes | Treatment Algorithms | Claims Data Analysis | US | 2021
Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes (T2D) drugs and dominate the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective, safer, and better-tolerated therapies, such as the sodium glucose cotransporter-2 (SGLT- 2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have provided physicians with a broad array of therapeutic options. Moreover, with a better understanding of T2D and its complications, individualization of treatment is becoming more common. Numerous branded agents from both established and recently emergent classes are now jostling for position in the treatment paradigm.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed T2D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed T2D patients?
- How have Steglatro, Ozempic, Rybelsus, and Jardiance been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of T2D patients receive drug therapy within one year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of T2D patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
CONTENT HIGHLIGHTS
Markets covered: United States.
Key companies: Eli Lilly, Merck, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Pfizer, Sanofi.
Key drugs: Afrezza, Apidra, Basaglar, Byetta, Humalog, Januvia, Jardiance, Lantus, Levemir, Metformin, Nesina, Novolog, Onglyza, Ozempic, Steglatro, Toujeo, Tradjenta, Tresiba, Trulicity, Victoza, Rybelsus.
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
